CAS 883561-04-4

CA 224

CAS : 883561-04-4

CA224 is a novel staphylococcal vaccine candidate that is being developed for use in cancer immunotherapy. It is a low-molecular-weight, calcium carbonate-based compound that has demonstrated anticancer activity in preclinical studies. CA224 induces an immune response against the surface proteins of Staphylococcus aureus and has been shown to be effective at reducing tumor size in animal models of breast cancer. The potential use of CA224 as a diagnostic agent for the detection of staphylococci has also been explored.

Formule : C₂₄H₂₂N₂O

Degré de pureté : Min. 95%

Masse moléculaire : 354.4 g/mol

Ref: 3D-IKB56104

CA224

CAS : 883561-04-4

CA224: selective oral Cdk4-cyclin D1 inhibitor, IC50=6.2μM, promotes apoptosis, has antitumor effects.

Formule : C₂₄H₂₂N₂O

Couleur et forme : Solid

Masse moléculaire : 354.44

Ref: TM-T61266